Embolotherapy Market

Overview

The global Embolotherapy Market was valued at USD 4.02 billion in 2025 and is projected to reach USD 8.10 billion by 2034, growing at a CAGR of 7.9% during the forecast period (2026–2034). The market growth is driven by, rising prevalence of chronic diseases requiring embolization procedures, increasing adoption of minimally invasive treatments, growing demand for advanced embolic agents and delivery devices, expanding use of embolotherapy in cancer treatment. The market is shifting from conventional permanent embolic agents such as detachable coils and non-resorbable microspheres toward next-generation liquid and bioresorbable embolics that offer more precise, conformal vessel occlusion with improved procedural efficiency. Government and institutional support for interventional radiology capacity building, favorable reimbursement coverage for embolization procedures in the United States and major European markets, and regulatory pathways such as the FDA's premarket approval (PMA) and 510(k) programs that have cleared multiple next-generation embolic agents since 2025, are collectively supporting continued clinical adoption and market expansion. By region, North America held the largest share of the embolotherapy market in 2025, supported by high procedure volumes, dense cath-lab and interventional radiology infrastructure, and favorable reimbursement. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by its large and expanding patient pool, rising healthcare investment, and improving access to advanced imaging and interventional radiology services across China, India, Japan, and South Korea.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Liquid and Bioresorbable Embolic Agents Emerging as a Transformational Trend

• Device developers are advancing next-generation liquid and bioresorbable embolic agents designed to conform precisely to irregular vessel anatomy and, in some cases, resorb after achieving a therapeutic effect, reducing concerns associated with permanent implants.
• New embolic technologies are increasingly being validated through prospective, randomized, multicenter clinical trials rather than retrospective or single-arm studies, raising the evidentiary bar for regulatory clearance and physician adoption.
• Professional bodies such as the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and the Society of Interventional Radiology (SIR) continue to update clinical practice guidelines and host dedicated hands-on device training on embolic agents and dosimetry systems, supporting standardized adoption across interventional radiology practices.
• Instylla, Inc. received U.S. FDA premarket approval for its Embrace Hydrogel Embolic System, the first liquid embolic agent approved for hypervascular tumor embolization on the basis of a prospective, randomized, controlled multicenter trial enrolling 150 patients, illustrating the shift toward higher-evidence liquid embolic technologies.

KEY MARKET DRIVER

Rising Global Cancer Burden and Growing Preference for Minimally Invasive Interventional Oncology is the Key Driver

• The increasing global incidence of liver, kidney, and other hypervascular tumors is expanding the addressable patient population for transarterial chemoembolization (TACE) and transarterial radioembolization (TARE)/SIRT procedures.
• Patients and physicians increasingly favor catheter-based embolization over open surgical resection because it offers shorter hospital stays, lower complication rates, and faster recovery, particularly for patients who are poor surgical candidates.
• Expanding regulatory approvals are broadening clinical use: in July 2025, the U.S. FDA approved an expanded indication for Sirtex Medical's SIR-Spheres Y-90 resin microspheres to include unresectable hepatocellular carcinoma, making it the only Y-90 radioembolization therapy approved in the U.S. for both hepatocellular carcinoma and metastatic colorectal cancer.
• Government initiatives such as the National Cancer Plan of the National Cancer Institute promote effective, lower-toxicity cancer treatments and image-guided interventions, supporting wider adoption of minimally invasive interventional oncology procedures, including embolotherapy, for cancer treatment.

KEY MARKET OPPORTUNITY

Consolidation and Expansion into Adjacent Interventional Therapies Creates Significant Market Opportunity

• Large device manufacturers are pursuing acquisitions that combine embolization portfolios with adjacent mechanical thrombectomy and neurovascular technologies to build comprehensive interventional platforms and cross-sell across call points.
• Growing use of drug-eluting and radioactive microspheres in combination with advanced dosimetry and imaging software is creating opportunities for bundled device-plus-software business models in interventional oncology.
• Continued venture and strategic investment in clinical-stage embolic technology developers is expanding the pipeline of next-generation bioresorbable and hydrogel-based embolic agents awaiting regulatory clearance.
• Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. in a transaction valuing Penumbra at approximately USD 14.5 billion in enterprise value, extending Boston Scientific's embolization and access portfolio into mechanical thrombectomy and neurovascular therapies and illustrating the scale of ongoing consolidation in the space.

Embolotherapy Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product

Embolic agents held the largest share of the embolotherapy market in 2025, supported by their widespread use in transarterial chemoembolization and radioembolization procedures for hepatocellular carcinoma and other hypervascular tumors, favorable reimbursement in developed markets, and a well-established base of regulatory-approved products from established manufacturers. Their versatility across bleeding control, vascular malformation treatment, and tumor embolization further strengthens demand, while ongoing product innovations are expanding their clinical applications.

Liquid embolic agents are projected to grow at the fastest CAGR during the forecast period, supported by recent regulatory approvals of hydrogel- and polymer-based liquid embolics validated through randomized controlled trials, their ability to conform precisely to complex vascular anatomy, and growing physician preference for agents that reduce catheter entrapment risk compared with particulate embolics.

Product categories include

• Embolic Agents (Dominating Segment)
• Liquid Embolic Agents (Highest CAGR Segment)
• Embolization Coils
• Detachable Balloons
• Support Devices

Analysis by Procedure

Transcatheter arterial embolization (TAE) held the largest market share in 2025, supported by its broad applicability across oncology, peripheral vascular, and hemorrhage-control indications and its established role as the foundational embolization technique in interventional radiology. Its relatively straightforward procedural workflow, growing availability of dedicated embolic agents, and expanding adoption in minimally invasive treatment pathways further supported demand across hospitals and specialized interventional centers.

Transarterial radioembolization (TARE) is projected to grow at the fastest CAGR during the forecast period, supported by expanding regulatory indications for Y-90 microsphere therapies, improved clinical outcomes relative to conventional chemoembolization in select liver cancer populations, and rising adoption of personalized dosimetry planning. Increasing use of multidisciplinary treatment approaches and advancements in image-guided delivery are further supporting the adoption of TARE across specialized oncology and interventional radiology centers.

Procedure categories include

• Transcatheter Arterial Embolization – TAE (Dominating Segment)
• Transarterial Radioembolization (Highest CAGR Segment)
• Transarterial Chemoembolization – TACE

Analysis by Application

Oncology held the largest market share in 2025 and is also is also projected to grow at the fastest CAGR during the forecast period, accounting for a substantial share of global procedure volume, driven by the high global incidence of liver and kidney cancers and the central role of embolization in interventional oncology treatment pathways for patients who are not candidates for surgical resection. Growing adoption of locoregional therapies, increasing use of embolization for tumor control, and advancements in image-guided interventional procedures are further supporting market expansion in oncology applications. Growing preference for minimally invasive locoregional therapies, increasing adoption of personalized treatment planning, and broader use of embolotherapy in unresectable tumors are further expected to accelerate market growth.

Application categories include

• Oncology (Dominating & Highest CAGR Segment)
• Peripheral Vascular Diseases
• Neurological Diseases
• Nephrological Disorders
• Gastrointestinal Disorders

Analysis by End User

Hospitals held the largest market share in 2025 and are also projected to grow at the fastest CAGR during the forecast period, supported by the concentration of interventional radiology suites, cath labs, and specialist physicians within hospital settings, along with the complexity and monitoring requirements of embolization procedures. Increasing investments in advanced imaging and catheterization infrastructure, growing availability of multidisciplinary cancer care, and rising patient preference for minimally invasive treatments are further strengthening embolotherapy adoption in hospitals. Growing healthcare expenditure, expansion of hospital-based interventional radiology services, and increasing adoption of image-guided minimally invasive procedures are further contributing to the rapid growth of the hospital segment.

End User categories include

• Hospitals (Dominating & Highest CAGR Segment)
• Ambulatory Surgical Centers (ASCs)

By Region

North America held the largest share of the global embolotherapy market in 2025, supported by high per-capita procedure volumes, dense interventional radiology and cath-lab infrastructure, and favorable reimbursement for embolization procedures under United States payer systems. The United States is the largest country market in the region, driven by a large base of hospital-based interventional oncology programs, advanced neurovascular care infrastructure, and rapid adoption of newly approved embolic technologies. Canada is witnessing steady growth in embolization procedure volumes, supported by expanding interventional radiology capacity within its public healthcare system and increasing adoption of minimally invasive vascular interventions. Mexico is expected to experience gradual market expansion as private hospital investments, improving specialist availability, and increasing access to interventional radiology procedures support the adoption of embolotherapy technologies.

Asia Pacific is projected to register the fastest CAGR during the forecast period, driven by its large and growing patient pool for cancer and vascular disorders, rising healthcare expenditure, and expanding interventional radiology capacity across China, India, Japan, and South Korea. China represents the largest country market in the region, supported by expanding hospital infrastructure, rising cancer treatment demand, and increasing adoption of transarterial embolization and radioembolization procedures. India is expected to witness strong growth as investments in advanced hospital infrastructure, specialist training, and minimally invasive treatment capabilities expand access to embolotherapy. Japan maintains a mature market supported by advanced healthcare infrastructure, a strong base of interventional radiology specialists, and domestic development of high-precision embolic devices, while South Korea benefits from advanced tertiary hospitals and early adoption of next-generation embolization technologies. Rest of Asia Pacific markets are expected to gain gradually as healthcare infrastructure, physician training, and access to minimally invasive therapies improve.

Countries and Region covered

North America

• United States (Largest Country Market)
• Canada
• Mexico

Europe

• Germany (Largest Country Market)
• United Kingdom
• France (Fastest-Growing Country Market)
• Italy
• Rest of Europe

Asia Pacific

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The market is consolidated, with a group of large, diversified medical device companies including Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Johnson & Johnson, Stryker Corporation, Abbott Laboratories, and Merit Medical Systems, Inc. holding significant positions through broad embolic agent and support device portfolios, global distribution networks, and continuous new product approvals. Alongside these global players, specialized interventional oncology and neurovascular manufacturers, such as Kaneka Corporation, Balt, Acandis GmbH, Instylla, Inc., Shape Memory Medical, Inc., Artio Medical, Inc., GEM S.r.l., and INVAMED, compete through clinical differentiation in specific procedure types, embolic technologies, and indications. Key success factors include regulatory clearance breadth, strength of clinical evidence, physician training and support infrastructure, and depth of distribution in hospital-based interventional radiology departments. Leading companies are prioritizing acquisitions and internal product development that extend embolization portfolios into adjacent neurovascular and interventional therapies, investment in liquid, polymer-based, and bioresorbable embolic technologies supported by clinical evidence, and expansion of manufacturing and clinical training capacity in higher-growth Asia-Pacific markets.

Key Players

• Boston Scientific Corporation (United States)
• Medtronic plc (Ireland)
• Terumo Corporation (Japan)
• Johnson & Johnson (United States)
• Stryker Corporation (United States)
• Abbott Laboratories (United States)
• Merit Medical Systems, Inc. (United States)
• Kaneka Corporation (Japan)
• Balt (France)
• Acandis GmbH (Germany)
• Instylla, Inc. (United States)
• Shape Memory Medical, Inc. (United States)
• Artio Medical, Inc. (United States)
• GEM S.r.l. (Italy)
• INVAMED (Turkey)

Recent Market Developments

• June 2025: Penumbra, Inc. announced FDA clearance and commercial launch of an expanded configuration within its Ruby coil embolization portfolio, broadening physician options for peripheral vascular and neurovascular embolization procedures.
• September 2025: Sirtex Medical received an expanded CE Mark approval for its SIR-Spheres Y-90 resin microspheres, broadening the eligible patient population in Europe to cover both primary and secondary liver metastases.
• November 2025: Kaneka began European sales of its i-ED COIL brain aneurysm embolization coil, expanding its embolotherapy presence following EU Medical Device Regulation certification in July 2025
• August 2026: Medtronic received U.S. FDA approval for Onyx 12 Liquid Embolic System for middle meningeal artery embolization in symptomatic subacute or chronic subdural hematoma, featuring lower viscosity and a 1-minute preparation time.

Frequently Asked Questions